| (b) | Address or principal business office or, if none, residence:
Biotechnology Value Fund, L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF I GP LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
Biotechnology Value Fund II, L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF II GP LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
Biotechnology Value Trading Fund OS LP
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
BVF Partners OS Ltd.
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
BVF GP Holdings LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF Partners L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF Inc.
44 Montgomery St., 40th Floor
San Francisco, California 94104
Mark N. Lampert
44 Montgomery St., 40th Floor
San Francisco, California 94104 |
| (a) | Amount beneficially owned:
As of the close of business on September 30, 2026, the Reporting Persons and a certain Partners managed account (the "Partners Managed Account") held an aggregate of 7,840,062 Warrants (the "Warrants") exercisable for an aggregate of 7,840,062 shares of the Issuer's Common Stock, par value $0.001 per share (the "Shares"). The Warrants are exercisable at an exercise price per Share equal to $3.289 per Share and may be exercised at any time, and will expire on July 2, 2029. A holder of the Warrants shall not have the right to exercise any portion of the Warrants if the holder, together with its affiliates, beneficially owns or would beneficially own in excess of 9.99% of the Shares that would be issued and outstanding following such exercise (the "Maximum Percentage"). As of the close of business on September 30, 2026, the Maximum Percentage prohibited the exercise of all of the Warrants held by the Reporting Persons and the Partners Managed Account.
As of the close of business on September 30, 2026, the Reporting Persons and the Partners Managed Account held pre-funded warrants (the "Pre-Funded Warrants") exercisable for an aggregate of 1,185,922 Shares. The Pre-Funded Warrants are exercisable at any time at an exercise price of $0.001 per Share and will not expire until exercised in full. Under the pre-funded warrants, the Issuer may not effect the exercise of any Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Pre-Funded Warrant, (i) if immediately prior to exercise the holder (together with its affiliates) beneficially owns an aggregate number of Shares greater than 9.99% of the number of Shares outstanding immediately before giving effect to the exercise of any Pre-Funded Warrant or (ii) to the extent that immediately following exercise, the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of Shares outstanding immediately after giving effect to the issuance of such Shares, and without taking into account any other Pre-Funded Warrants (the "Pre-Funded Warrants Blocker"). As of the close of business on September 30, 2026, the Pre-Funded Warrants Blocker limits the exercise of the Pre-Funded Warrants by the Reporting Persons and the Partners Managed Account to 119,443 out of 1,185,922 Shares underlying the Pre-Funded Warrants held by them.
As of the close of business on September 30, 2026, the Reporting Persons and the Partners Managed Account held an aggregate of 6,723,600 common warrants (the "Common Warrants") exercisable for an aggregate of 6,723,600 Shares. The Common Warrants are exercisable at any time at an exercise price of $3.50 per Share. The Common Warrants will expire at 5:00 p.m. (New York City time) on the earlier of (A) the fifth anniversary of November 13, 2026 (the "Charter Amendment Effective Date") and (B) the 30th calendar day following the later of the Charter Amendment Effective Date and the date on which the Issuer publicly discloses the results of the overall survival analysis for its Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and later recurrent or metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC), which is expected in the first half of 2027. Under the Common Warrants, the Issuer may not effect the exercise of any Common Warrant, and a holder will not be entitled to exercise any portion of any Common Warrant, (i) if immediately prior to exercise the holder (together with its affiliates) beneficially owns an aggregate number of Shares greater than 9.99% of the number of Shares outstanding immediately before giving effect to the exercise of any Common Warrant or (ii) to the extent that immediately following exercise, the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of Shares outstanding immediately after giving effect to the issuance of such Shares, and without taking into account any other Common Warrants (the "Common Warrants Blocker"). As of the close of business on September 30, 2026, the Common Warrants Blocker prohibited the exercise of all of the Common Warrants held by the Reporting Persons and the Partners Managed Account.
As of the close of business on September 30, 2026, (i) BVF beneficially owned 6,250,280 Shares, including 119,443 Shares underlying certain Pre-Funded Warrants held by it and excluding (a) 480,287 Shares underlying certain Pre-Funded Warrants held by it, (b) 3,400,176 Shares underlying certain Common Warrants held by it and (c) 4,115,047 Shares underlying the Warrants held by it, (ii) BVF2 beneficially owned 4,609,217 Shares, excluding (a) 453,820 Shares underlying the Pre-Funded Warrants held by it, (b) 2,572,947 Shares underlying the Common Warrants held by it and (c) 3,083,847 Shares underlying the Warrants held by it, and (iii) Trading Fund OS beneficially owned 844,116 Shares, excluding (a) 96,934 Shares underlying the Pre-Funded Warrants held by it, (b) 549,601 Shares underlying the Common Warrants held by it and (c) 518,280 Shares underlying the Warrants held by it.
BVF GP, as the general partner of BVF, may be deemed to beneficially own the 6,250,280 Shares beneficially owned by BVF.
BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 4,609,217 Shares beneficially owned by BVF2.
Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 844,116 Shares beneficially owned by Trading Fund OS.
BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 10,859,497 Shares beneficially owned in the aggregate by BVF and BVF2.
Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 11,945,583 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, including 241,970 Shares held in the Partners Managed Account, which excludes (a) 35,438 Shares underlying the Pre-Funded Warrants held by it, (b) 200,876 Shares underlying the Common Warrants held by it and (c) 122,888 Shares underlying the Warrants held by it.
BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 11,945,583 Shares beneficially owned by Partners.
Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 11,945,583 Shares beneficially owned by BVF Inc.
The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities. |
| (b) | Percent of class:
The following percentages are based upon a denominator that is the sum of: (i) 83,408,050 Shares outstanding as of August 12, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2026, (ii) 36,047,919 Shares issued in the Issuer's direct offering, as reported in the Issuer's Prospectus Supplement filed with the Securities and Exchange Commission on October 1, 2026 and (iii) 119,443 Shares underlying certain Pre-Funded Warrants held by the Reporting Persons as applicable.
As of the close of business on September 30, 2026, (i) BVF beneficially owned approximately 5.2% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 3.9% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 5.2% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 3.9% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 9.1% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.99% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).
(c) Number of shares as to which the person has: |